Key result
Canonical heart failure therapies and new treatments such as sacubitril/valsartan, iron supplements, and serelaxin show promise in improving survival and symptoms in elderly patients.
Why the study?
Heart failure remains highly prevalent in the aging population, prompting review of classical therapies alongside emerging treatments for elderly patients.
This review summarizes classical and emerging pharmacological therapies for heart failure specifically tailored to the growing elderly population.
HF burden in elderly set to surge with aging populations; leaves open optimal geriatric care integration beyond canonical therapies.
Heart failure (HF) is a complex clinical syndrome, with high prevalence in the elderly. The World Heath Organization (WHO) predicts that by 2050 the population aged over 80 years will account around 400 million, reflecting that HF will still represent a major public health concern. Improved management of cardiovascular diseases and HF, together with the increased life expectancy explains, at least in part, the high prevalence of HF especially in the elderly. Beside the canonical therapy for HF failure, including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and aldosterone antagonists, new potential and promising therapies, such as sacubitril/valsartan, iron deficiency treatment and serelaxine, are emerging also in elderly HF patients. In this review we focus on the classical recommended HF therapy and the possible application of new trends in elderly.
No takes yet. Share an insight, caveat, or question.
Komici et al. (2018) conducted a review in Heart failure. Heart failure therapies (canonical and new trends) was evaluated. Canonical heart failure therapies and new treatments such as sacubitril/valsartan, iron supplements, and serelaxin show promise in improving survival and symptoms in elderly patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: